Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
![Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira[®]](/_up/ucb_com_presscenter/images/presscenter_teaser_20.jpg?300)
Twitter Feed
-
One vertebral fracture occurs every 22 seconds worldwide in men and women over age 50! Our novel #bonebot aims to detect these #fragilityfractures which have a detrimental impact on daily living. Learn more here: https://t.co/nuB5wAp01D #RSNA19 https://t.
— UCB News (@ucb_news) 09.12.2019 -
For some people, #ITP can be an ‘invisible disease’ with symptoms that can't always be seen and can come and go. Look out for these symptoms. #ASH19 https://t.co/wgWt2HJdFk https://t.co/R6jYK2lVRL
— UCB News (@ucb_news) 08.12.2019 -
Immune thrombocytopenia (#ITP) is a severe, often chronic disease that can affect people physically, professionally and emotionally. We're at #ASH19 to share our latest research as part of our mission to help people with this devastating disease. http
— UCB News (@ucb_news) 07.12.2019
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
